Scarica l'app Stockscreener
9.96
4.87%
-0.51
Dopo l'orario di chiusura:
9.96
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Storia dei dividendi
Precedente Chiudi:
$10.47
Aprire:
$10.49
Volume 24 ore:
1.73M
Relative Volume:
0.75
Capitalizzazione di mercato:
$1.69B
Reddito:
$68.56M
Utile/perdita netta:
$-437.99M
Rapporto P/E:
-3.148
EPS:
-3.1639
Flusso di cassa netto:
$-396.61M
1 W Prestazione:
-14.87%
1M Prestazione:
-5.32%
6M Prestazione:
-3.58%
1 anno Prestazione:
+71.72%
Intervallo 1D:
$9.91
$10.49
Intervallo di 1 settimana:
$9.91
$11.82
Portata 52W:
$4.815
$12.00
Vir Biotechnology Inc Stock (VIR) Company Profile
Nome
Vir Biotechnology Inc
Settore
Industria
Telefono
415-906-4324
Indirizzo
1800 OWENS STREET, SAN FRANCISCO, CA
Compare VIR vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VIR
Vir Biotechnology Inc
|
9.96 | 1.69B | 68.56M | -437.99M | -396.61M | -3.1639 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Vir Biotechnology Inc Stock (VIR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-24 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2025-09-03 | Iniziato | Evercore ISI | Outperform |
| 2025-08-27 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-01-29 | Downgrade | JP Morgan | Overweight → Neutral |
| 2023-09-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-03-06 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-02-21 | Aggiornamento | Goldman | Neutral → Buy |
| 2023-01-27 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-09-14 | Iniziato | SVB Leerink | Outperform |
| 2022-09-09 | Iniziato | Morgan Stanley | Underweight |
| 2022-03-03 | Aggiornamento | Robert W. Baird | Underperform → Neutral |
| 2021-12-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2021-10-25 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2021-09-22 | Downgrade | Goldman | Buy → Neutral |
| 2021-06-04 | Ripresa | Robert W. Baird | Neutral |
| 2021-01-27 | Downgrade | JP Morgan | Neutral → Underweight |
| 2021-01-20 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-09-14 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-09-11 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2020-08-20 | Iniziato | Needham | Buy |
| 2020-03-19 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-03-13 | Downgrade | Goldman | Buy → Neutral |
| 2020-02-27 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2020-02-04 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-11-14 | Iniziato | Robert W. Baird | Neutral |
| 2019-11-05 | Iniziato | Barclays | Overweight |
| 2019-11-05 | Iniziato | Cowen | Outperform |
| 2019-11-05 | Iniziato | Goldman | Buy |
| 2019-11-05 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Vir Biotechnology Inc Borsa (VIR) Ultime notizie
Can Gilead's Deal With VIR Boost Its Oncology Pipeline and Growth? - Zacks Investment Research
Can Vir Biotechnology (NASDAQ:VIR) Keep Climbing After Latest Target Boost? - Kalkine Media
Aziz Sawaf, CFO of Vir Biotechnology (VIR), reports zero directly held common shares. - Stock Titan
One talk will cover hepatitis D response data through 96 weeks; another will study liver immune cells. - Stock Titan
A $150K sign-on bonus, contingent on continued employment, awaits Vir Biotechnology (VIR)'s incoming CFO. - Stock Titan
Vir Biotechnology, Inc. (NASDAQ:VIR) Stock Rated "Moderate Buy" by Sell-Side Brokerages - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Nears Key Hepatitis Delta Readout - kalkinemedia.com
Vir Biotechnology (NasdaqGS:VIR) Stock Forecast & Analyst Predictions - Simply Wall Street
Vir Biotechnology Stock Price Forecast. Should You Buy VIR? - StockInvest.us
Engineers Gate Manager LP Sells 121,964 Shares of Vir Biotechnology, Inc. $VIR - MarketBeat
Former Vir (NASDAQ: VIR) officer sold $315K in stock, with more share sales planned - Stock Titan
WINTON GROUP Ltd Trims Stake in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology (VIR) ex-officer to sell 28,333 shares from option exercise - Stock Titan
How (VIR) Movements Inform Risk Allocation Models - Stock Traders Daily
Legal & General Group Plc Invests $2.76 Million in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology, Inc. (NASDAQ:VIR) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Bank of New York Mellon Corp Makes New $7.08 Million Investment in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology stock gains on conference catalyst - ad-hoc-news.de
Man Group plc Takes $1.54 Million Position in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology stock gains on new 52-week high and conference appearance - ad-hoc-news.de
Corient Private Wealth LP Invests $3.17 Million in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology (NASDAQ:VIR) Sets New 52-Week HighShould You Buy? - MarketBeat
Vir Biotechnology stock gains on conference participation and 52-week high - ad-hoc-news.de
Vir Biotechnology stock hits 52-week high at 11.66 USD By Investing.com - Investing.com South Africa
Vir Biotechnology stock hits 52-week high at 11.66 USD By Investing.com - Investing.com Canada
Vir Biotechnology stock hits 52-week high at 11.66 USD By Investing.com - Investing.com India
Vir Biotechnology stock hits 52-week high at 11.66 USD By Investing.com - Investing.com Nigeria
Vir Biotechnology stock hits 52-week high at 11.66 USD - investing.com
Vir Biotechnology stock hits 52-week high at 11.66 USD By Investing.com - Investing.com UK
Vir Biotechnology (NASDAQ:VIR) Trading 4.8% HigherHere's What Happened - MarketBeat
Vir Biotechnology to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference - Business Wire
Vir Biotechnology CEO to speak at Morgan Stanley conference Sept. 14 - Stock Titan
Deutsche Bank AG Acquires Shares of 134,258 Vir Biotechnology, Inc. $VIR - MarketBeat
ARCH Venture Management LLC Invests $129.35 Million in Vir Biotechnology, Inc. $VIR - MarketBeat
Algert Global LLC Purchases 315,969 Shares of Vir Biotechnology, Inc. $VIR - MarketBeat
ADAR1 Capital Management LLC Acquires New Shares in Vir Biotechnology, Inc. $VIR - MarketBeat
Vir Biotechnology (NASDAQ: VIR) ex-officer lines up more sales - Stock Titan
Vir Biotechnology (NASDAQ:VIR) Shares Up 8.1%Time to Buy? - MarketBeat
Vir Biotechnology (NASDAQ: VIR) officer plans 14,352-share sale after 25K sale - Stock Titan
Vir Biotechnology (NASDAQ: VIR) ex-officer files notice for potential $245K stock sale - Stock Titan
Vir Biotechnology on Track for Record Winning Streak -- Data Talk - Bitget
Vir (VIR) Close and Levels: Adds 1.06% to Close at $9.49 in the Latest Reading; Key Levels: the $9.02 to $9.96 Range Remains in Focus in Latest TradingRevenue Weighted - vinanet.vn
The Bull Case For Vir Biotechnology (VIR) Could Change Following A Sudden Swing To Quarterly Profitability - Sahm
Vir Biotechnology’s Earnings Call Signals Data-Driven Momentum - TipRanks
The Bull Case For Vir Biotechnology (VIR) Could Change Following A Sudden Swing To Quarterly Profitability - simplywall.st
The Bull Case For Vir Biotechnology (VIR) Could Change Following A Sudden Swing To Quarterly Profitability - simplywall.st
Vir Biotechnology (VIR) Climbs 2.67% to $9.24 as Trading Volume Picks UpETH Profile - vinanet.vn
Vir Biotechnology, Inc. (VIR) Stock Forecasts - Yahoo Finance
Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript - The Globe and Mail
Vir Biotechnology (VIR) Q2 2026 Earnings Call Transcript - AOL.com
Vir Biotechnology Inc Azioni (VIR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Vir Biotechnology Inc Azioni (VIR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| O'Byrne Jason | Former Officer |
Sep 09 '26 |
Proposed Sale |
11.13 |
28,333 |
315,241 |
0 |
| O'Byrne Jason | Former Officer |
Aug 25 '26 |
Proposed Sale |
10.48 |
23,148 |
242,591 |
0 |
| O'Byrne Jason | Former Officer |
Aug 24 '26 |
Proposed Sale |
9.90 |
14,352 |
142,124 |
0 |
| O'Byrne Jason | Former Officer |
Aug 21 '26 |
Proposed Sale |
9.81 |
25,000 |
245,297 |
0 |
| Ramasastry Saira | Former Director |
Jun 29 '26 |
Proposed Sale |
10.32 |
16,000 |
165,139 |
0 |
| Napolitano Janet | Director |
Jun 01 '26 |
Sale |
9.45 |
3,200 |
30,240 |
21,216 |
| Sabatini Brent | SVP, Chief Accounting Officer |
Jun 01 '26 |
Sale |
9.45 |
379 |
3,582 |
61,902 |
| Sabatini Brent | Officer |
Jun 01 '26 |
Proposed Sale |
9.45 |
379 |
3,582 |
0 |
| Napolitano Janet | Director |
Jun 01 '26 |
Proposed Sale |
9.45 |
3,200 |
30,240 |
0 |
| SATO VICKI L | Director |
May 01 '26 |
Sale |
10.05 |
22,000 |
221,025 |
1,078,391 |
5.60%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):